Loading...
•
Mar 31, 2024
ACADIA Q1 2024 Earnings Report
Acadia reported first quarter financial results and operating overview.
Key Takeaways
Acadia Pharmaceuticals reported net product sales of $205.8 million, representing 74% revenue growth year over year, driven by DAYBUE and NUPLAZID.
NUPLAZID net product sales were $129.9 million.
DAYBUE net product sales were $75.9 million.
Net income was $16.6 million, or $0.10 per common share.
Cash, cash equivalents and investment securities totaled $470.5 million.
Revenue by Segment
Forward Guidance
Acadia is reiterating all of its 2024 guidance provided on February 27, 2024.
Positive Outlook
- DAYBUE net product sales guidance in the range of $370 to $420 million.
- NUPLAZID net product sales guidance in the range of $560 to $590 million.
- R&D expense in the range of $305 to $325 million.
- SG&A expense in the range of $455 to $480 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...